Octagon Capital Advisors’s RAPT Therapeutics RAPT Stock Holding History

Octagon Capital Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-574,000	Closed	-$19.4M	–	34
2025 Q4	$19.4M	Buy	+574,000	New	+$17.8M	2.36%	17
2024 Q4	–	Sell	-36,500	Closed	-$587K	–	46
2024 Q3	$587K	Hold	36,500	–	–	0.09%	41
2024 Q2	$891K	Hold	36,500	–	–	0.14%	44
2024 Q1	$2.62M	Hold	36,500	–	–	0.31%	49
2023 Q4	$7.26M	Buy	+36,500	New	+$4.52M	1.16%	20

Octagon Capital Advisors's RAPT Position: Q1 2026 in Review

Octagon Capital Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 574,000 shares — an estimated $19.4M sold.

Octagon Capital Advisors first reported a position in RAPT in Q4 2023 and held it in 5 quarters. The position peaked at $19.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Octagon Capital Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Octagon Capital Advisors sold 574,000 RAPT Therapeutics shares in Q1 2026, an estimated $19.4M.
Octagon Capital Advisors first reported a position in RAPT Therapeutics in Q4 2023 and held it in 5 quarters.
Octagon Capital Advisors's RAPT Therapeutics position peaked at $19.4M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.